Business Wire

Exscientia Enters $70M Collaboration to Develop Antiviral Therapeutics Against Coronavirus and Other Viruses With Pandemic Potential

Share

Exscientia, an AI-driven pharmatech company with a mission to radically improve how drugs are discovered, today announced a four-year collaboration with the Bill & Melinda Gates Foundation, a non-profit focused on fighting global poverty, disease, and inequity, to develop small molecule therapeutics that tackle the current coronavirus pandemic and help prepare for future pandemics. The collaboration will initially focus on developing broad-spectrum coronavirus agents (e.g., SARS-CoV-2 and its variants, MERS), including accelerating Exscientia’s lead programme, which targets the main protease (Mpro) of SARS-CoV-2, the virus responsible for COVID-19. Subsequently, the collaboration will expand to develop therapeutics for influenza and Paramyxoviridae (e.g., Nipah), with the potential to develop additional programmes as identified by the joint team.

Exscientia’s AI-driven platform enables scientific concepts to be rapidly translated into precision-designed therapeutic candidates, with a goal of increasing probability of success and an accelerated path to the patient.

“The ongoing COVID-19 pandemic underscores the urgency to develop safe and effective broad-spectrum drugs to expand our armoury against viruses and their variants. We need to fight today’s pandemic but also ensure we are prepared with new drugs to combat viruses with future pandemic potential. We are honoured to work alongside the Bill & Melinda Gates Foundation to advance this mission by ensuring accessibility and affordability of these therapeutics globally,” commented Andrew Hopkins, Chief Executive Officer of Exscientia. “We believe that our AI-driven platform can accelerate the creation of better, more effective therapeutics that can address some of the world’s most critical and emerging health risks.”

"Small molecule therapeutics could provide a superior approach to guard global health," said Denise Barrault, Director of Portfolio Management at Exscientia. "Certain targets are prevalent across families of viruses, meaning that potent therapeutics could be broadly effective across multiple virus families. Further, this collaboration will focus on evaluating protein targets that are evolutionarily conserved and are less likely to develop resistance.”

The Gates Foundation’s programme-related investment in Exscientia was made through its Strategic Investment Fund (SIF), a team that uses a suite of financial tools to address market failures and incentivise private enterprise to develop affordable and accessible products and services for low-income populations. SIF investments are intended to further the Gates Foundation’s programmatic goals, not to generate financial returns. If any profit is generated by an investment, it will be used solely for charitable purposes through Gates Foundation philanthropic programmes.

Under the terms of the agreement, Exscientia will receive a $35 million equity investment from the SIF, with the potential for additional grant funding to help advance development candidates through commercialisation. The Gates Foundation’s programme-related investment is subject to certain closing conditions being satisfied. As a global leader in pandemic preparedness, the Gates Foundation will also contribute its extensive expertise in funding the design, development, and distribution of antiviral drugs. Exscientia will lead the initial antiviral projects and apply its platform technology to research, discover, and develop up to five Phase 1-ready small molecule therapeutics for future pandemic preparedness. Exscientia will provide $35 million in matching contributions, through operations and funding for third party activities. Exscientia maintains worldwide rights to all developed products with a commitment to make the antiviral products affordable and accessible to people in developing countries.

In July, Exscientia received a grant from the Gates Foundation to expedite the optimisation of a new class of COVID-19 therapeutics created using its AI drug design platform, focused on a novel class of inhibitors targeting the SARS-CoV-2’s main protease enzyme, Mpro, the causative agent of COVID-19. This work will continue under the collaboration announced today. Additionally, in 2020, the foundation awarded a $4.2 million grant to Exscientia to identify new innovative treatments for malaria and tuberculosis – two of the world’s leading infectious disease killers – as well as new medicines for non-hormonal contraception.

About Exscientia

Exscientia is an AI-driven pharmatech company committed to discovering, designing, and developing the best possible drugs in the fastest and most effective manner. Exscientia is the first company to progress AI-designed small molecules into the clinical setting and repeatedly demonstrate the ability of AI to transform how drug candidates are created. Exscientia’s AI platform has now designed three drugs that are in Phase 1 human clinical trials.

Drug design is precision engineering at the molecular scale. Exscientia has built dedicated AI systems that efficiently learn from the widest range of data and consistently reapply enhanced knowledge through iterations of design. Because Exscientia’s AI platform learns more effectively and rapidly than human-led efforts alone, candidate molecules satisfying complex therapeutic requirements are created with revolutionary efficiency. Exscientia believes that designing better drugs, faster, will allow the best ideas of science to rapidly become the best medicines for patients.

Exscientia has offices in Oxford, Vienna, Dundee, Miami and Osaka. For more information visit us at https://www.exscientia.ai or follow us on Twitter @exscientiaAI.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Exscientia Enquiries:

Edelman PR (UK)
Nathan Field
P: +44 (0)7866 411198
Nathan.Field@edelman.com

Edelman PR (US)
Amanda Lazaro
Amanda.Lazaro@edelman.com

Exscientia
Amanda Galgay
contact@exscientia.ai

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Moody’s Announces Participation in New GFANZ Alliance: Commits to Align Products and Services to Achieve Net-Zero Greenhouse Gas Emissions by 205022.9.2021 02:01:00 EEST | Press release

Moody’s Corporation (NYSE: MCO) today announced its participation in launching the Net Zero Financial Services Provider Alliance as part of the Glasgow Financial Alliance for Net Zero (GFANZ). As a founding member, Moody’s commits to align all of its relevant products and services to achieve net-zero greenhouse gas emissions by 2050, in addition to reducing its own operational emissions. “Climate change is the world’s greatest risk multiplier and a profound challenge for economies and communities alike. The entire financial industry must take on the shared challenge of enabling an urgent shift to a resilient and sustainable economy. Aligning products and services with net-zero by 2050 will improve decision-making and accelerate the flow of capital to support the transition,” said Rob Fauber, President and Chief Executive Officer of Moody’s Corporation. “We are delighted to join the Net Zero Financial Services Provider Alliance as our latest step to empower organizations in making more

Former Irish Prime Minister Bertie Ahern Announces The World Carbon Neutrality Forum22.9.2021 02:01:00 EEST | Press release

The "World Carbon Neutrality Forum" (WCNF) was announced today by the former President of the European Council (2004) and former Irish Prime Minister Bertie Ahern. Mr Ahern is currently co-chair of the Interaction of Council of Former Heads of State and Government, and the Eco Global Forum. The date of 22nd September has been chosen to mark the first anniversary of President Xi’s double carbon commitment and his efforts towards a community with a shared future. The Forum is established to promote climate cooperation between China, the United States, Europe, and the rest of the World. In its first year of operation, the World Carbon Neutrality Forum will be held virtually and transmitted by a dedicated video platform called the World Carbon Neutrality Media Network. The Forum will be based on a Davos model and will seek to stimulate thoughts globally by leadership on decarbonisation. It is a pluralistic organisation which will meet each quarter and will invite current and former Heads o

Science, Innovation, and Inclusion Are Vital in Addressing the World’s Most Pressing Issues, Says PMI CEO in Speech at Concordia Summit21.9.2021 23:24:00 EEST | Press release

Jacek Olczak, Chief Executive Officer of Philip Morris International Inc. (PMI) (NYSE: PM), today delivered remarks at the 2021 Concordia Annual Summit. Olczak discussed the need to draw on the lessons learned from the global response to COVID-19 and create transparent frameworks and partnerships that harness innovation to build a better world. He explained the importance of focusing on peer-reviewed science to tackle major global issues—including environmental pressure, social inequality, health pandemic, and smoking. Olczak described how the exclusionary practices of many anti-tobacco organizations and NGOs are making it harder for PMI to deliver tobacco harm reduction solutions by introducing scientifically substantiated alternatives as the company moves away from making and selling cigarettes. The Concordia Annual Summit, which coincides with the United Nations General Assembly (UNGA) meeting, convenes the world’s most prominent business, government, and nonprofit leaders to foster

‘Hidden Gem’ Arrives in Rotterdam to be Transformed into Nodule Collection Vessel for The Metals Company21.9.2021 19:37:00 EEST | Press release

The Metals Company (Nasdaq: TMC) today announced that the 228-meter-long former drill ship renamed the Hidden Gem has arrived in Rotterdam, The Netherlands to begin its conversion into what is expected to be the first ship classified as a sub-sea mining vessel by the American Bureau of Shipping. TMC’s strategic partner Allseas acquired the former ultra-deep-water drill ship, which can accommodate 200 people, in March of 2020, as her configuration is well-suited for modifications that will enable the deployment at sea of a 4.5 kilometer-long riser to bring polymetallic nodules up from the seafloor. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005945/en/ Hidden Gem vessel (Photo: Business Wire) In partnership with The Metals Company (formerly DeepGreen Metals Inc.), Allseas is developing a deep-sea mineral collection system to responsibly recover polymetallic nodules from the ocean floor and transfer them to the surfac

Rhizen Pharmaceuticals AG Announces First Patient Dosed in a Phase 2 Study of RP7214 in Covid-19 Patients21.9.2021 19:36:00 EEST | Press release

Rhizen Pharmaceuticals AG, a clinical-stage oncology & inflammation-focussed biopharmaceutical company, today announced that the first patient has been dosed in a Phase 2 clinical trial of RP7214, a small molecule oral dihydroorotate dehydrogenase (DHODH) Inhibitor. The randomized, double-blind, placebo-controlled, Phase 2 study will evaluate the efficacy & safety of oral RP7214, in covid-19 patients with mild, symptomatic disease with an underlying risk factor on the background of promising preclinical efficacy & phase 1 healthy volunteer safety. The study is being conducted in India across 12 centres in coordination with Rhizen’s India affiliate, Incozen Therapeutics Pvt ltd., and is designed to enrol up to 204 patients across both study arms. Viral replication involves a huge demand for building blocks and relies on nucleotides derived from host cells. DHODH is a rate-limiting enzyme in the pyrimidine biosynthesis pathway, inhibition of which leads to depletion of host nucleotide po

Citi Private Bank Finds Cautious Optimism Among Investors for 2022 with Covid-19, Inflation and Peak Market Valuations Top of Mind21.9.2021 19:31:00 EEST | Press release

Citi Private Bank’s Private Capital Group today released the results of its 2021 Family Office Survey, compiling the unique perspectives and insights of many of the world’s sophisticated family offices and ultra-high net worth investors in a challenging climate. This year’s survey included nearly 200 responses, an 11% increase from 2020. Four predominant themes emerged: 1) concern on rising inflation, 2) the prominence of high cash levels in the face of low yield environment, 3) continued growth in portfolio allocation to direct investing opportunities, and 4) a marked comeback in portfolio values year over year despite prevalent degree of macroeconomic uncertainty. While over three-fourths of all respondents seek returns of 5% or more over the next 12 months, the outlook is more optimistic for family offices with AUM over $500 million with 30% seeking over 10% returns versus 19% of family offices with AUM under $500 million. This likely factors in the additional institutional tools an

SSIMWAVE Selects Verimatrix Code Protection to Prevent Reverse Engineering of its Award-Winning Video Experience Platform21.9.2021 18:45:00 EEST | Press release

Regulatory News: Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced that Ontario, Canada-based SSIMWAVE Inc. is one of its latest customers to integrate Verimatrix Code Protection technology. IP theft is a growing threat to organizations worldwide. The Commission on the Theft of American Intellectual Property estimates that costs from IP losses are as high as $600 billion annually. “Verimatrix has a lengthy and successful history in the media and entertainment space, so it made sense to turn to their code protection technologies,” said Peter Olijnyk, Vice President of Engineering at SSIMWAVE. “When you’re protecting the core foundation of your platform, Verimatrix’s transparent and timely process for getting up and running – not to mention in about a day or so – was reassuring and provides peace of mind for SSIMWAVE and our customers.” A video quality innovator, SSIMWAVE evaluated numerous vendors and deci

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom